Mario Salvi

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials.

Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials.

Journal: Ophthalmology

Published: April 29, 2026

EndoBridge 2025: pearls and highlights.

EndoBridge 2025: pearls and highlights.

Journal: Hormones (Athens, Greece)

Published: March 26, 2026

What has changed in thyroid eye disease in the last five years (2020-2025).

What has changed in thyroid eye disease in the last five years (2020-2025).

Journal: European thyroid journal

Published: November 18, 2025

Horizon scanning from panel discussions at the EUGOGO Global TED Forum 2025 London.

Horizon scanning from panel discussions at the EUGOGO Global TED Forum 2025 London.

Journal: Eye (London, England)

Published: November 15, 2025

The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease.

The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease.

Journal: Reviews in endocrine & metabolic disorders

Published: October 29, 2025

Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report.

Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report.

Journal: Thyroid research

Published: October 24, 2025

Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab.

Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab.

Journal: European thyroid journal

Published: November 18, 2023

Response to Letter to the Editor From Lui et al: "Increased Risk of Thyroid Eye Disease Following COVID-19 Vaccination".

Response to Letter to the Editor From Lui et al: "Increased Risk of Thyroid Eye Disease Following COVID-19 Vaccination".

Journal: The Journal of clinical endocrinology and metabolism

Published: October 04, 2023

Clinical and Visual Outcomes of Dysthyroid Optic Neuropathy After Surgical Orbital Decompression.

Clinical and Visual Outcomes of Dysthyroid Optic Neuropathy After Surgical Orbital Decompression.

Journal: Thyroid : official journal of the American Thyroid Association

Published: May 04, 2023

Increased Risk of Thyroid Eye Disease Following Covid-19 Vaccination.

Increased Risk of Thyroid Eye Disease Following Covid-19 Vaccination.

Journal: The Journal of clinical endocrinology and metabolism

Published: May 04, 2023

SARS-COV-2 specific t-cells in patients with thyroid disorders related to COVID-19 are enriched in the thyroid and acquire a tissue-resident memory phenotype.

SARS-COV-2 specific t-cells in patients with thyroid disorders related to COVID-19 are enriched in the thyroid and acquire a tissue-resident memory phenotype.

Journal: Clinical immunology (Orlando, Fla.)

Published: March 28, 2023

Long-term outcome of thyroid abnormalities in patients with severe Covid-19.

Long-term outcome of thyroid abnormalities in patients with severe Covid-19.

Journal: European thyroid journal

Published: January 12, 2023

Showing 1-12 of 56

Last Updated: 09/26/2026